{"id":"NCT01854658","sponsor":"Pearl Therapeutics, Inc.","briefTitle":"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)","officialTitle":"A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2013-05-15","resultsPosted":"2017-03-28","lastUpdate":"2017-03-28"},"enrollment":1615,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"GFF MDI (PT003)","otherNames":["glycopyrrolate/formoterol fumarate metered-dose inhaler","(GFF MDI)"]},{"type":"DRUG","name":"GP MDI (PT001)","otherNames":["glycopyrrolate metered dose inhaler (GP MDI)"]},{"type":"DRUG","name":"FF MDI (PT005)","otherNames":["formoterol fumarate metered dose inhaler (FF MDI)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"FF MDI (PT005)","type":"EXPERIMENTAL"},{"label":"GP MDI (PT001)","type":"EXPERIMENTAL"},{"label":"GFF MDI (PT003)","type":"EXPERIMENTAL"},{"label":"Placebo MDI","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multicenter, randomized, double-blind, parallel group, chronic-dosing (24 weeks), placebo-controlled study to assess the efficacy and safety of Glycopyrrolate (GP and Formoterol Fumarate (FF) combination metered-dose inhaler (MDI) (GFF; PT003), GP MDI (PT001), and FF MDI (PT005) compared with Placebo MDI in subjects with moderate to very severe COPD.","primaryOutcome":{"measure":"Change From Baseline in Morning Pre-dose Trough FEV1","timeFrame":"At Week 24","effectByArm":[{"arm":"FF MDI (PT005)","deltaMin":0.061,"sd":null},{"arm":"GP MDI (PT001)","deltaMin":0.063,"sd":null},{"arm":"GFF MDI (PT003)","deltaMin":0.116,"sd":null},{"arm":"Placebo MDI","deltaMin":0.013,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":113,"countries":["United States"]},"refs":{"pmids":["35815359","32450869","32021148","28720336"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4151&filename=PT003007-02%20Protocol%20Amendment-FINAL-11Sept14_29June16_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":438},"commonTop":["Nasopharyngitis"]}}